@article{cd2f368f76994afe8379850394886f52,
title = "Evolution of congenital haemophilia care in Taiwan",
abstract = "Haemophilia care in Taiwan has come a long way over the past 35 years, from the absence of specialised haemophilia treatment centres before 1984 to the establishment of treatment centers in the majority of medical centers, the listing of haemophilia as a catastrophic illness with full treatment reimbursement by the Taiwan National Health Insurance (NHI), and the implementation of full NHI coverage for prophylaxis therapy. This has led to outcome improvements such as reduced bleed-related morbidity and mortality, fewer viral infections, and enhanced overall multi-modality care. Most people with haemophilia (PWH) are now able to live normal, active lives. Early diagnosis has improved through increased awareness, physician education, and prenatal diagnosis; while comprehensive care, including state of the art rehabilitation and orthopaedic management for haemophilic arthropathy, eradication therapy for chronic hepatitis C, and better treatments for human immunodeficiency virus, allows PWH to enjoy a better quality of life and improved survival. Efforts are now being made to raise prophylaxis rates through full NHI reimbursement and the use of extended half-life recombinant factor products. Overall, Taiwan has made great strides in haemophilia care and we would like to share these experiences for the benefit of all healthcare providers involved in haemophilia care.",
keywords = "Arthropathy, Comprehensive care, Haemophilia, Prophylaxis, Taiwan",
author = "Chen, {Yeu Chin} and Chang, {Chia Yau} and Cheng, {Shin Nan} and Pan, {Ru Yu} and Shih, {Yu Lueng} and Li, {Tsung Ying} and Wang, {Sheng Hao}",
note = "Funding Information: The authors would like to thank Dr. Vivek R. Sharma, Research Scientist and Medical Director at the Adult Hemophilia Program, Division of Medical Oncology/Hematology, University of Louisville School of Medicine, for his critical review of this manuscript. We thank Kevin Yang, MD, an employee of Sanofi Taiwan, for his critical insights, proofreading, and technical editing of the manuscript. Editorial support for the writing of this manuscript was provided by GlobalMedNews, and was funded by Sanofi Taiwan . The authors maintained full editorial control of the manuscript and retained final approval of all content. This sponsorship did not affect research design, data collection, data analysis, the decision to publish, and the choice of the journal in any way. Funding Information: The authors would like to thank Dr. Vivek R. Sharma, Research Scientist and Medical Director at the Adult Hemophilia Program, Division of Medical Oncology/Hematology, University of Louisville School of Medicine, for his critical review of this manuscript. We thank Kevin Yang, MD, an employee of Sanofi Taiwan, for his critical insights, proofreading, and technical editing of the manuscript. Editorial support for the writing of this manuscript was provided by GlobalMedNews, and was funded by Sanofi Taiwan. The authors maintained full editorial control of the manuscript and retained final approval of all content. This sponsorship did not affect research design, data collection, data analysis, the decision to publish, and the choice of the journal in any way. Publisher Copyright: {\textcopyright} 2021",
year = "2022",
month = mar,
doi = "10.1016/j.jfma.2021.07.017",
language = "English",
volume = "121",
pages = "582--591",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier B.V.",
number = "3",
}
